This review examines clinical evidence for guava's therapeutic efficacy across multiple health domains. Randomized controlled trials reveal guava's significant impacts on metabolic health, demonstrating reduced postprandial glucose responses, improved lipid profiles, and decreased blood pressure. Nutritional intervention studies establish guava as an effective food-based strategy for improving iron status in vulnerable populations through enhanced iron absorption, particularly in children and pregnant women. Additional clinical evidence supports guava's applications in musculoskeletal health (reducing knee pain), dermatological care (controlling sebum production), oral health (preventing gingivitis and reducing oral pathogens), and gastrointestinal disorders (alleviating diarrheal symptoms). These diverse therapeutic effects stem from guava's rich phytochemical profile, including flavonoids, carotenoids, and exceptionally high vitamin C content. The review highlights guava's versatility as a well-tolerated, accessible intervention that aligns with sustainable, food-based approaches to health management. While current evidence provides a foundation for guava's clinical applications, future research should further elucidate mechanisms of action, optimize preparations, and explore additional therapeutic potential. Guava emerges as a scientifically validated therapeutic agent with significant potential to improve health outcomes across diverse populations and conditions.

Diabetic neuropathy, a painful complication of diabetes mellitus, may potentially be treated with compounds found in cocoa pods. This study investigates the interactions of various flavonoids (catechin, epicatechin, quercetin, luteolin, apigenin, naringenin, and procyanidin) contained in the cocoa pod to the Canonical Transient Receptor Potential (TRPC6) receptor. Molecular docking, facilitated by Autodock software, was employed to predict the binding affinities of these compounds to TRPC6. This involved preparing the molecular structures of the flavonoids and the TRPC6 protein for simulation. The simulation provided insights into the binding efficiencies and interaction energies between the flavonoids and TRPC6. The findings indicate that procyanidin and quercetin exhibit the highest binding energies, at -7.15 kcal/mol and -6.37 kcal/mol, respectively. Procyanidin interacts with the amino acid residues Ala508, Arg609, Arg758, Asn765, Asp530, Glu512, His446, and Met505, while quercetin binds to Arg758, Asp530, Glu512, and Glu524. These results highlight the potential of quercetin and procyanidin as candidates for the development of TRPC6-targeted treatments for diabetic neuropathy. This study lays the groundwork for the creation of new, effective, and safe diabetic neuropathy medications.

Sarmoko, Nisa Yulianti Suprahman, Anjar Hermadi Saputro, Iwan Syahjoko Saputra, Khaerunnisa Anbar Istiadi, Arif Fadlan, Fadilah, I Gede Raditya Purwanata, Vito Rahmat Fitrah. J Pharmacopuncture 2026;29:61-74. https://doi.org/10.3831/KPI.2026.29.1.61

Psoriasis is a chronic immune-mediated inflammatory skin disorder characterized by keratinocyte hyperproliferation, persistent inflammation, dysregulated apoptosis, and tissue remodeling. Momordica charantia has attracted attention as a potential anti-psoriatic herbal candidate; however, the molecular basis of its bioactive metabolites remains insufficiently understood. This study investigated the anti-psoriatic potential of cucurbitane-type triterpenoids from M. charantia using integrated network pharmacology and molecular docking. Of 192 secondary metabolites, 50 passed pharmacokinetic and toxicity screening, yielding 347 predicted human targets, of which 159 overlapped with 3,383 psoriasis-associated genes. Key hub genes identified by protein-protein interaction and topological analyses included AKT1, TNF, EGFR, STAT3, IL1B, CASP3, MMP9, HIF1A, and ESR1, with enriched biological processes related to oxidative stress, lipid and hormonal responses, and intracellular receptor signaling. Molecular docking of five cucurbitane-type triterpenoids against four validated hub proteins demonstrated consistently favorable predicted binding affinities for AKT1 via its allosteric pocket, as well as for EGFR and IL1B. Karavilagenin A showed the most favorable binding energy against AKT1, momordicin I against EGFR and IL1B, and cucurbitacin B demonstrated favorable profiles across multiple targets. These findings suggest that M. charantia may influence psoriasis-related biology through multi-target mechanisms, providing a basis for further experimental validation.